Company: UPC
Filing Date: 2025-09-03
Form Type: 6-K
Source: 0001213900-25-084040
Chunk: 0

Company: Universe Pharmaceuticals INC
Filing Date: 2025-09-03
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission file number: 001-40231

Universe Pharmaceuticals INC

265 Jingjiu Avenue

Jinggangshan Economic and Technological Development Zone

Ji’an, Jiangxi, China 343100

+86-0796-8403309

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒
Form 40-F ☐</div>

Result of the 2025 Annual General Meeting of Shareholders

On September 2, 2025, Universe Pharmaceuticals
INC (the “Company”) re-convened its annual general meeting of shareholders, originally convened on August 26, 2025 (the “2025
Annual General Meeting”) at 10:00 a.m., Beijing Time, at 265 Jingjiu Avenue, Jinggangshan Economy and Technology Development Zone,
Ji’an City, Jiangxi 343100, the People’s Republic of China.

At the 2025 Annual General Meeting, the shareholders
of the Company adopted resolutions approving all of the proposals considered at the Meeting. A total of 2.55% of the 563,338 votes exercisable
as of July 18, 2025, the record date, were present in person or by proxy at the 2025 Annual General Meeting, representing less than one-third
(1/3) of the shares carrying the right to vote at the 2025 Annual General Meeting. However, since the 2025 Annual General Meeting was
adjourned from August 26, 2025 at 10:00 a.m. Beijing Time due to a lack of quorum, and shareholders representing less than one-third (1/3)
of the shares carrying the right to vote were present in person or by proxy at the 2025 Annual General Meeting within fifteen minutes
of the time appointed for the 2025 Annual General Meeting, the shareholders present or by proxy shall constitute a quorum in accordance
with article